The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs
| Autor: | Hong-Ge Zhu, Chang-Jun Zhu, Hou Yanshen, Ting-Chuan Xiong, Yang-Chun Feng, Jia Song, Wei Jiang, Yuan Zhang |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
0301 basic medicine Oncology medicine.medical_specialty Lung Neoplasms Neutrophils lymphocyte-to-monocyte ratio Observational Study Leukocyte Count 03 medical and health sciences 0302 clinical medicine neutrophil-to-lymphocyte ratio Epidermal growth factor Carcinoma Non-Small-Cell Lung Internal medicine tyrosine kinase inhibitors Biomarkers Tumor medicine Carcinoma Humans Lymphocytes Epidermal growth factor receptor Neutrophil to lymphocyte ratio Aged Univariate analysis Receiver operating characteristic biology Proportional hazards model business.industry General Medicine Middle Aged Protein-Tyrosine Kinases Prognosis medicine.disease respiratory tract diseases ErbB Receptors 030104 developmental biology 030220 oncology & carcinogenesis Mutation biology.protein Female epidermal growth factor receptor business Tyrosine kinase Research Article nonsmall cell lung cancer |
| Zdroj: | Medicine |
| ISSN: | 0025-7974 |
| DOI: | 10.1097/md.0000000000011648 |
| Popis: | Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are the standard first-line treatment for EGFR-mutant nonsmall cell lung cancer (NSCLC) patients. However, studies have reported that not all NSCLC patients harboring kinase domain mutations in epidermal growth factor receptor (EGFR) show significant clinical benefits from EGFR-targeted tyrosine kinase inhibitors (TKIs). Therefore, it is necessary to establish feasible biomarkers to predict the prognosis of EGFR-mutant NSCLC patients treated with EGFR-TKIs. This study aimed to determine biomarkers using inflammatory parameters from complete blood counts to predict the prognosis of EGFR-mutant NSCLC patients treated with EGFR-TKIs. We retrospectively investigated 127 stage IIIB/IV NSCLC patients with activating EGFR mutations who were treated with EGFR-TKIs. We used receiver operating characteristic (ROC) curves to determine the optimal cut-off for the inflammatory markers as prognostic factors. Additionally, univariate and multivariate analyses were used to identify prognostic factors for progression-free survival (PFS) and overall survival (OS) of EGFR-mutant NSCLC patients treated with EGFR-TKIs. The receiver operating characteristic analysis indicated that the lymphocyte-to-monocyte ratio (LMR) and neutrophil-to-lymphocyte ratio (NLR) cut-off values were 3.37 and 2.90, respectively. The univariate analysis showed that a high LMR (>3.37) and low NLR (≤2.90) were significantly correlated with long-term PFS and OS (LMR, P = .007; NLR, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|